María Diez‐Campelo

Multivariate time‐dependent comparison of the impact of lenalidomide in lower‐risk myelodysplastic syndromes with chromosome 5q deletion

Joaquín Sánchez‐García, Consuelo del Cañizo, Ignacio Lorenzo et al. · British Journal of Haematology · 2014 · 18 citations · Full text

Medicine, Hematology, Oncology +15

Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome

Teresa Bernal, María Diez‐Campelo, Vicky Godoy et al. · Leukemia Research · 2014 · 18 citations · Full text

Medicine, Hematology, Oncology +17

Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial

María Diez‐Campelo, Félix López Cadenas, Blanca Xicoy et al. · The Lancet Haematology · 2024 · 16 citations

Medicine, Hematology, Pharmacology +13

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients - Interim Analysis of the European Sintra-REV Trial

Félix López Cadenas, Eva Lumbreras, Blanca Xicoy et al. · Blood · 2020 · 10 citations

Medicine, Hematology, Oncology +7